Zurueck zur Suche

Reporte zur Charge UJ662AAA

Verknuepft ueber VAERS_ID mit VAERSDATA, Vax und Symptoms

3Reporte angezeigt
0Todesfaelle
0Hospitalisiert
0Lebensbedrohlich
0Bleibende Schaeden
CO 2 NY 1

VAERS 2630164

UNKNOWN MANUFACTURER · VACCINE NOT SPECIFIED (NO BRAND NAME) · Charge UJ662AAA

gering
Staat
NY
Alter
0,5
Geschlecht
F
Eingang
11.05.2023
Impfdatum
08.05.2023
Beginn
08.05.2023
Tage bis Beginn
0,0
Dosis
3
Route/Site
OT / RL
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Expired product administered No adverse event

Symptomtext

expired product was administered to a patient with no reported adverse event; Initial information received on 08-May-2023 regarding an unsolicited valid non-serious case received from other health professional. This case involves a 6 months old female patient who was administered expired vaccine diphtheria/tetanus/5 hybrid AC pertussis/IPV(VERO)/HIB(PRP/T) vaccine [Pentacel (Vero)] with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. Concomitant medications included rotavirus vaccine; hepatitis B vaccine; pneumococcal vaccine conj 7V (CRM197) (Prevnar); and influenza vaccine for Immunisation. On 08-May-2023, the patient received an expired 0.5 mL (dose number: 3) of suspect diphtheria/tetanus/5 hybrid AC pertussis/IPV(vero)/HIB(PRP/T) vaccine, suspension for injection (batch number: UJ662AAA; Expiry date: 04-May-2023) via intramuscular route in the right thigh for immunization with no reported adverse event (expired product administered) (same day latency). The reporter was not aware of any adverse reactions post administration. Action taken: not applicable. At time of reporting, the outcome was Unknown for the event expired product was administered to a patient with no reported adverse event. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Expired product administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2569854

SANOFI PASTEUR · DTAP + IPV + HIB (PENTACEL) · Charge UJ662AAA

gering
Staat
CO
Alter
0,3
Geschlecht
M
Eingang
28.01.2023
Impfdatum
23.01.2023
Beginn
23.01.2023
Tage bis Beginn
0,0
Dosis
2
Route/Site
OT / RL
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
No adverse event Single component of a two-component product administered

Symptomtext

component of PENTACEL given without the Hib component with no reported adverse event; Initial information received on 24-Jan-2023 regarding an unsolicited valid non-serious case received from a other health professional. This case involves a 4 months old male patient who was exposed to component of pentacel given without the hib component with no reported adverse event while receiving vaccine Diphtheria/Tetanus/5 Hybrid AC Pertussis/IPV(MRC5)/HIB(PRP/T) Vaccine [Pentacel]. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. Concomitant medications included Pneumococcal vaccine CONJ 13V (CRM197) (Prevnar 13) for Prophylactic vaccination; and Rotavirus vaccine live reassort oral 5V (Rotateq) for Prophylactic vaccination. On 23-Jan-2023, the patient received a 0.5 ml dose 2 of suspect Diphtheria/Tetanus/5 Hybrid AC Pertussis/IPV(MRC5)/HIB(PRP/T) Vaccine Suspension for injection with component of pentacel given without the hib component with no reported adverse event (single component of a two-component product administered) (lot: UJ662AAA) via intramuscular route in the right thigh with frequency: once, strength: standard, expiry date: 02-Apr-2023 for immunization. Action taken: not applicable. Outcome: unknown. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.

Weitere VAERSDATA-Felder
Praegender Schweregrund
No adverse event
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2527394

UNKNOWN MANUFACTURER · VACCINE NOT SPECIFIED (NO BRAND NAME) · Charge UJ662AAA

gering
Staat
CO
Alter
1,0
Geschlecht
F
Eingang
09.12.2022
Impfdatum
01.12.2022
Beginn
01.12.2022
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
OT / RL
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Incorrect product formulation administered Medication error No adverse event Product preparation error

Symptomtext

mixed PENTACEL with the wrong diluent and administered it to a patient with no AE; mixed PENTACEL with the wrong diluent and administered it to a patient with no AE; Initial information was received on 02-Dec-2022 regarding an unsolicited valid non-serious case received from a other health professional. This case involves a 1 years old female patient for whom pentacel was mixed with the wrong diluent and administered it to a patient with no adverse event after receiving diphtheria/tetanus/5 hybrid AC pertussis/IPV(MRC5)/HIB(PRP/T) vaccine [Pentacel]. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. Concomitant medications included influenza vaccine, measles vaccine, mumps vaccine, rubella vaccine (MMR) and varicella zoster vaccine (varicella vaccine) for Immunisation. On 01-Dec-2022, the patient received 0.25 ml dose of suspect diphtheria/tetanus/5 hybrid AC pertussis/IPV(MRC5)/HIB(PRP/T) vaccine (Suspension for injection) (lot: UJ662AAA, expiry date: 04-May-2023, strength: Standard, frequency: once) via intramuscular route in the right vastus lateralis for Immunization. On 01-Dec-2022 the patient had a non-serious event mixed pentacel with the wrong diluent and administered it to a patient with no adverse event (incorrect product formulation administered) (Product preparation error) same day following the administration of diphtheria/tetanus/5 hybrid AC pertussis/IPV(MRC5)/HIB(PRP/T) vaccine. Action taken: not applicable. It was not reported if the patient received a corrective treatment for the event. At time of reporting, the outcome was Unknown for the event. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Incorrect product formulation administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
INFLUENZA VACCINE; MMR; VARICELLA VACCINE
Allergien
-
Vorherige Impfungen
-